Skip to Content

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

The FRESCO-2 phase III trial evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer is one of several studies Marco Gerlinger, Professor of Gastrointestinal Cancer Medicine at Barts Cancer Institute (BCI), Queen Mary University of London present in this MEDtalk with highlights from ESMO for treatment of lower gastrointestinal tumors.

Marco Gerlinger

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top